Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).
Elias AD, Skarin AT, Leong T, Mentzer S, Strauss G, Lynch T, Shulman L, Jacobs C, Abner A, Baldini EH, Frei E 3rd, Sugarbaker DJ.
Elias AD, et al. Among authors: skarin at.
Lung Cancer. 1997 May;17(1):147-61. doi: 10.1016/s0169-5002(97)00658-2.
Lung Cancer. 1997.
PMID: 9194034
Clinical Trial.
Pathologic complete response was observed in five patients (15%) and an additional unresectable patient had fibrosis-only documented at thoracotomy for an overall clinicopathologic response rate of 76% (18% pathologic CR). ...While radiographic response generally correlate …
Pathologic complete response was observed in five patients (15%) and an additional unresectable patient had fibrosis-only documented at …